1. [18F]FDHT tumour imaging for predicting response to treatment based on androgen receptor.
- Author
-
Muhammad, Abdullah Mujahid, Dun, Wenhao, Ashhar, Zarif, and Ahmad Fadzil, Muhammad Fakhrurazi
- Subjects
- *
PROSTATE-specific membrane antigen , *ANDROGEN receptors , *CASTRATION-resistant prostate cancer , *ANDROGEN deprivation therapy , *LIGANDS (Biochemistry) - Abstract
The preliminary role of [18F]fluoro-5α-dihydrotestosterone ([18F]FDHT) in identifying receptor status and managing cancer patients is promising. In this work, we compiled studies regarding the ability of [18F]FDHT to predict response to treatment in different stages of drug development. In the chemical development, the androgen receptor (AR) ligands of [18F]FDHT were the candidates evaluated and identified using preclinical methods. High uptake of [18F]FDHT levels was observed in cell lines and xenograft tumours in mice having glucuronidation-competent cells mimicking the sensitive type of castration-resistant prostate cancer (CRPC) treated with androgen deprivation therapy (ADT). In clinical trials, the detection of lesions with [18F]FDHT was in agreement with the standard radiotracer [18F]FDG in advanced prostate cancer (PC) and was even better in AR-positive without glycolytic activity (AR1Glyc0) subtypes, demonstrating the specific role of [18F]FDHT for the detection of tumour localisation. Moreover, the immunohistochemistry (IHC) correlation between [18F]FDHT and AR was stronger than the correlation between [68 Ga]Ga-PSMA-11 and prostate-specific membrane antigen (PSMA), suggesting that [18F]FDHT can be a standalone modality for the monitoring of AR-targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF